Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Immunocore, Genentech Expand Anti-Cancer Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Immunocore, Genentech Expand Anti-Cancer Alliance

To co-develop Immunocore’s IMC-C103C candidate, an ImmTAC molecule targeting tumors that express the protein MAGE-A4

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Immunocore Ltd., a T Cell Receptor (TCR) biotechnology company, has entered into a new partnership with Genentech, a member of the Roche Group, to expand an existing discovery collaboration to co-develop Immunocore’s IMC-C103C candidate, an ImmTAC molecule targeting tumors that express the protein MAGE-A4 (Melanoma-Associated Antigen A4).

Immunocore will lead the first-in-human trial to establish safety and preliminary efficacy of IMC-C103C as both monotherapy and in combination with Genentech’s atezolizumab (Tecentriq). The  trial, which is scheduled to begin in early 2019, will enroll patients across a number of solid tumor types. Genentech will pay Immunocore $100 million in upfront and near-term milestone payments. Upon establishing proof-of-concept data, Immunocore retains an option to continue to co-develop IMC-C103C through commercialization, or to fully license the candidate to Genentech in return for royalty and milestone payments.

Andrew Hotchkiss, chief executive ofifcer of Immunocore, said, “MAGE-A4 is a known cancer-associated antigen expressed in a wide range of malignancies.  Genentech is a leader in oncology with extensive immunology expertise, with whom we’ve had a good collaborative relationship for several years. We look forward to embarking upon this new partnership to investigate whether IMC-C103C could ultimately improve the lives of people with MAGE-A4 positive cancers.”

James Sabry, M.D., Ph.D., global head of Pharma Partnering, Roche, said, “We’ve had a very productive collaboration with Immunocore since we began our initial partnership in 2013.  We’re excited to move this first molecule forward, both as a single agent and in combination with Tecentriq, and to further explore the role of T cell receptor-directed medicines in fighting cancer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics